Buyout firm GTCR is nearing a deal to buy generic drugmaker Zentiva in a deal that could be valued at about $4.8 billion, according to people familiar with the matter.
www.bloomberg.com
#GTCR #Billion #Deal #Buy #Advents #Zentiva
GTCR Is Said to Near $4.8 Billion Deal to Buy Advent’s Zentiva
